Poolbeg Pharma PLC (POLB.L) LSE
Currency In GBp
- General
- Statistics
- Historical Data
- Profile
- Financials
Poolbeg Pharma PLC
Address
Queen Mary BioEnterprises Innovation Ctr
London, E1 2AX
United Kingdom of Great Britain and Northern Ireland (the)
Phone
44 20 7183 1499
Sector
Healthcare
Industry
Biotechnology
Employees
15
First IPO Date
July 19, 2021
Key Executives
| Name | Title | Pay | Year Born |
| Jeremy Skillington | Chief Executive Officer & Director | 332,000 | 1971 |
| Cathal Martin Friel | Executive Chairman of The Board | 151,000 | 1964 |
| Ian O'Connell | Chief Financial Officer & Director | 235,000 | 1987 |
| Carol Dalton | Vice President of Investor Relations & Public Relations | 0 | N/A |
| Ross Crockett | Group Financial Controller | 0 | N/A |
| Liam Tremble | Principal Scientist | 0 | N/A |
Description
Poolbeg Pharma plc is a clinical-stage biopharmaceutical company based in the United Kingdom, focused on developing treatments for infectious diseases. Its pipeline features several key programs: POLB 001, a p38 MAP Kinase inhibitor intended for severe influenza; POLB 002, a pioneering, in-licensed RNA-based immunotherapy administered intranasally to combat respiratory virus infections; and POLB 003, an intramuscular vaccine aimed at preventing Melioidosis. Beyond specific therapeutic candidates, Poolbeg also holds licensed access to advanced micro- and nanoencapsulation technology for an oral vaccine delivery system designed to stimulate gut immunity. The company further advances its research through an artificial intelligence-powered drug program. Additionally, Poolbeg is developing a biomarker platform to identify individuals at high risk of severe disease, alongside a model-derived vaccine discovery platform to pinpoint novel vaccine candidates. Incorporated in 2021, Poolbeg Pharma plc is headquartered in London.
